

Tomohiro Asai, Ph. D.

Institution: Department of Medical Biochemistry, Graduate Division of Pharmaceutical Sciences,
University of Shizuoka
Position: Associate Professor
E-Mail: asai@u-shizuoka-ken.ac.jp
Address: 52-1 Yada, Suruga-ward, Shizuoka-city, Shizuoka 422-8526, Japan
Tel: +81 54-264-5703, FAX: +81 54-264-5705

Education:

Apr. 1999 to Mar. 2002 Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka,
Japan. (Ph. D.)
Apr. 1999 to Mar. 2002 Research Fellowships of the Japan Society for the Promotion of Science
Apr. 1997 to Mar. 1999 Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka,
Japan. (M. Sc.)
Apr. 1993 to Mar. 1997 School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
(B. Sc.)

Professional Experience:

Apr. 2013 to present Associate Professor, Department of Medical Biochemistry, Graduate Division
of Pharmaceutical Sciences, University of Shizuoka
Feb. 2004 to Mar. 2013 Assistant Professor, Department of Medical Biochemistry, Graduate Division
of Pharmaceutical Sciences, University of Shizuoka
Jul. 2011 to Jun. 2012 Visiting Scholar, Division of Molecular Pharmaceutics, Eshelman School of
Pharmacy, University of North Carolina
Oct. 2005 to Dec. 2005 Visiting Scholar, Division of Drug Delivery and Disposition, Eshelman School
of Pharmacy, University of North Carolina
Apr. 2002 to Jan. 2004 Researcher, Mitsubishi Pharma Corporation

Membership:

The Pharmaceutical Society of Japan
The Japan Society of Drug Delivery System (Councilor)
The Academy of Pharmaceutical Science and Technology, Japan (Councilor)
The Japanese Biochemical Society

Awards:

- 1) The APSTJ Award for Young Pharmaceutical Scientist (May 2014)
- 2) The Pharmaceutical Society of Japan Tokai Branch Award for Young Scientists (Jul. 2011)
- 3) The Pharmaceutical Society of Japan Award for Young Scientists (Mar. 2011)
- 4) The APSTJ Global Education Seminar Presentation Award 2009 (Oct. 2009)

- 5) The 28th Pharmaceutical Science and Technology Seminar Postdoctoral Presentation Award (Jul. 2003)
- 6) University of Shizuoka Habataki Award (Nov. 2000)
- 7) The 9th Symposium of The Japanese Association for Metastasis Research Presentation Award (Jun. 2000)
- 8) The 7th Liposomes Research Days Conference Poster Award (Apr. 2000)

Bibliography (Original Publications):

- 1) Fukuta T, Asai T, Yanagida Y, Namba M, Koide H, Shimizu K, Oku N: Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. *FASEB J.* in press
- 2) Okuda K, Fu HY, Matsuzaki T, Araki R, Tsuchida S, Thanikachalam PV, Fukuta T, Asai T, Yamato M, Sanada S, Asanuma H, Asano Y, Asakura M, Hanawa H, Hao H, Oku N, Takashima S, Kitakaze M, Sakata Y, Minamino T: Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats. *PLoS One.* **11**, e0160944 (2016) doi: 10.1371/journal.pone.0160944.
- 3) Fukuta T, Asai T, Ishii T, Koide H, Kiyokawa C, Hashimoto M, Kikuchi T, Shimizu K, Harada N, Tsukada H, Oku N: Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity. *Sci. Rep.* **6**, 30127 (2016) doi: 10.1038/srep30127.
- 4) Fukuta T, Asai T, Sato A, Namba M, Yanagida Y, Kikuchi T, Koide H, Shimizu K, Oku N: Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. *Int. J. Pharm.* **506**, 129-137 (2016) doi: 10.1016/j.ijpharm.2016.04.046.
- 5) Koide H, Okamoto A, Tsuchida H, Ando H, Ariizumi S, Kiyokawa C, Hashimoto M, Asai T, Dewa T, Oku N: One-step encapsulation of siRNA between lipid-layers of multi-layer polycation liposomes by lipoplex freeze-thawing. *J. Control. Release* **228**, 1-8 (2016) doi: 10.1016/j.jconrel.2016.01.032.
- 6) Ishida Y, Kiyokawa Y, Asai T, and Oku N: Ameliorating effects of sphingomyelin-based liposomes on sarcopenia in senescence-accelerated mice. *Biol. Pharm. Bull.* **39**,786-793 (2016) doi: 10.1248/bpb.b15-00915.
- 7) Shimizu K, Miyauchi H, Urakami T, Yamamura-Ichikawa K, Yonezawa S, Asai T, Oku N: Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its anti-allergic effect. *J. Drug Target.* 1-29 (2016)
- 8) Okamoto A, Asai T, Ryu S, Ando H, Maeda N, Dewa T, Oku N: Enhanced efficacy of doxorubicin by microRNA-499-mediated improvement of tumor blood flow. *J. Clin. Med.* **5**, 10 (2016) doi: 10.3390/jcm5010010.
- 9) Fukuta T, Ishii T, Asai T, Sato A, Kikuchi T, Shimizu K, Minamino T, Oku N: Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions. *Eur. J. Pharm. Biopharm.* **97**, 1-7 (2015) doi: 10.1016/j.ejpb.2015.09.020.
- 10) Koide H, Asai T, Kato H, Yonenaga N, Yokota M, Ando H, Dewa T, Nango M, Maeda N, Oku N: Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin. *Nanomedicine* **11**, 185-194 (2015) doi: 10.1016/j.nano.2014.09.003.
- 11) Yahuafai J, Asai T, Nakamura G, Fukuta T, Siripong P, Hyodo K, Ishihara H, Kikuchi H, Oku N: Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin. *J. Control. Release* **192**, 167-173 (2014) doi: 10.1016/j.jconrel.2014.07.010.
- 12) Fukuta T, Ishii T, Asai T, Nakamura G, Takeuchi Y, Sato A, Agato Y, Shimizu K, Akai S, Fukumoto D, Harada N, Tsukada H, Kawaguchi AT, Oku N: Real-time trafficking of PEGylated liposomes in the rodent focal brain ischemia analyzed by positron emission tomography. *Artif. Organs* **38**, 662-666 (2014) doi: 10.1111/aor.12350.

- 13) Okamoto A, [Asai T](#), Kato H, Shimizu K, Ando H, Minamino T, Mekada E, Oku N: Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF. *Biochem. Biophys. Res. Commun.* **449**, 460-465 (2014) doi: 10.1016/j.bbrc.2014.05.043.
- 14) Ando H, [Asai T](#), Koide H, Okamoto A, Maeda N, Tomita K, Dewa T, Minamino T, Oku N: Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499. *J. Control. Release* **181**, 32-39 (2014) doi: 10.1016/j.jconrel.2014.02.019.
- 15) Yasuda N, Ishii T, Oyama D, Fukuta T, Agato Y, Sato A, Shimizu K, [Asai T](#), Asakawa T, Kan T, Yamada S, Ohizumi Y, Oku N: Neuroprotective effect of nobiletin on cerebral ischemia-reperfusion injury in transient middle cerebral artery-occluded rats. *Brain Res.* **1559**, 46-54 (2014) doi: 10.1016/j.brainres.2014.02.007.
- 16) [Asai T](#), Tsuzuku T, Takahashi S, Okamoto A, Dewa T, Nango M, Hyodo K, Ishihara H, Kikuchi H, Oku N: Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. *Biochem. Biophys. Res. Commun.* **444**, 599-604 (2014) doi: 10.1016/j.bbrc.2014.01.107.
- 17) Shimizu K, Asakawa T, Harada N, Fukumoto D, [Asai T](#), Yamada S, Kan T, Oku N: Use of positron emission tomography for real-time imaging of biodistribution of green tea catechin. *PLoS One.* **9**, e85520 (2014) doi: 10.1371/journal.pone.0085520.
- 18) Ando H, Okamoto A, Yokota M, [Asai T](#), Dewa T, Oku N: Polycation liposomes as a vector for potential intracellular delivery of microRNA. *J. Gene Med.* **15**, 375-383 (2013) doi: 10.1002/jgm.2744.
- 19) Sugiyama T, [Asai T](#), Nedachi MY, Katanasaka Y, Shimizu K, Maeda N Oku N: Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors. *PLoS One.* **8**, e67550 (2013) doi: 10.1371/journal.pone.0067550.
- 20) Ishii T, [Asai T](#), Oyama D, Agato Y, Yasuda N, Fukuta T, Shimizu K, Minamino T, Oku N: Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506. *FASEB J.* **27**, 1362-1370 (2013) doi: 10.1096/fj.12-221325.
- 21) Ichikawa K, [Asai T](#), Shimizu K, Yonezawa S, Urakami T, Miyauchi H, Kawashima H, Ishida T, Kiwada H, Oku N: Suppression of immune response by antigen-modified liposomes encapsulating model agents: A novel strategy for the treatment of allergy. *J. Control. Release* **167**, 284-289 (2013) doi: 10.1016/j.jconrel.2013.02.002.
- 22) Takahama H, Shigematsu H, [Asai T](#), Matsuzaki T, Sanada S, Fu HY, Okuda K, Yamato M, Asanuma H, Asano Y, Asakura M, Oku N, Komuro I, Kitakaze M, Minamino T. Liposomal Amiodarone Augments Anti-arrhythmic Effects and Reduces Hemodynamic Adverse Effects in an Ischemia/Reperfusion Rat Model. *Cardiovasc. Drugs Ther.* **27**, 125-132 (2013) doi: 10.1007/s10557-012-6437-6.
- 23) Ishii T, Fukuta T, Agato Y, Oyama D, Yasuda N, Shimizu K, Kawaguchi AT, [Asai T](#), Oku N: Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfusion is reduced. *Biochem. Biophys. Res. Commun.* **430**, 1201-1205 (2013) doi: 10.1016/j.bbrc.2012.12.080.
- 24) Kenjo E, [Asai T](#), Yonenaga N, Ando H, Ishii T, Hatanaka K, Shimizu K, Urita U, Dewa T, Nango M, Tsukada H, Oku N: Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. *Biol. Pharm. Bull.* **36**, 287-291 (2013)
- 25) Ando H, Okamoto A, Yokota M, Shimizu K, [Asai T](#), Dewa T, Oku N: Development of miR-92a delivery system for antiangiogenesis-based cancer therapy. *J. Gene Med.* **15**, 20-27 (2013) doi: 10.1002/jgm.2690.
- 26) Ishii T, [Asai T](#), Fukuta T, Oyama D, Yasuda N, Agato Y, Shimizu K, Minamino T, Oku N: A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion. *Int. J. Pharm.* **439**, 269-274 (2012) doi: 10.1016/j.ijpharm.2012.09.026.
- 27) Koide H, [Asai T](#), Kato H, Ando H, Shiraishi K, Yokoyama M, Oku N: Size-dependent induction of accelerated

- blood clearance phenomenon by repeated injections of polymeric micelles. *Int. J. Pharm.* **432**, 75-79 (2012) doi: 10.1016/j.ijpharm.2012.04.049.
- 28) Ishii T, Asai T, Oyama D, Fukuta T, Yasuda N, Shimizu K, Minamino T, Oku N: Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. *J. Control. Release* **160**, 81-87 (2012) doi: 10.1016/j.jconrel.2012.02.004.
- 29) Yonenaga N, Kenjo E, Asai T, Tsuruta A, Shimizu K, Dewa T, Nango M, Oku N: RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. *J. Control. Release* **160**, 177-181 (2012) doi: 10.1016/j.jconrel.2011.10.004.
- 30) Nishikawa K, Asai T, Shigematsu H, Shimizu K, Kato H, Asano Y, Takashima S, Mekada E, Oku N, Minamino T: Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. *J. Control. Release* **160**, 274-280 (2012) doi: 10.1016/j.jconrel.2011.10.010.
- 31) Tokutomi K, Tagawa T, Korenaga M, Chiba M, Asai T, Watanabe N, Takeoka S, Handa M, Ikeda Y, Oku N: Ability of fibrinogen γ -derived dodecapeptides with different sequences to bind to rat platelets. *Int J Pharm.* **438**, 296-301 (2012) doi: 10.1016/j.ijpharm.2012.09.016.
- 32) Ogata M, Yano M, Umemura S, Murata T, Park EY, Kobayashi Y, Asai T, Oku N, Nakamura N, Matsuo I, Usui T: Design and synthesis of high-avidity tetravalent glycoclusters as probes for sambucus sieboldiana agglutinin and characterization of their binding properties. *Bioconjug. Chem.* **23**, 97-105 (2012) doi: 10.1021/bc200440e.
- 33) Asai T, Matsushita S, Kenjo E, Tsuzuku T, Yonenaga N, Koide H, Hatanaka K, Dewa T, Nango M, Maeda N, Kikuchi H, Oku N: Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery. *Bioconjug. Chem.* **22**, 429-435 (2011) doi: 10.1021/bc1004697.
- 34) Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N, Oku N: Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with siRNA in VEGFR-1-targeting vector. *Biol. Pharm. Bull.* **34**, 602-608 (2011)
- 35) Umemoto T, Asai T, Hirashima K, Shimizu K, Mihara M, Yamamoto K, Kubota K, Miyagawa S, Oku N: Proapoptotic action of p53-Tom5 in p53-resistant A549 human non-small cell lung cancer cells through direct mitochondrial dysfunction. *Biol. Pharm. Bull.* **34**, 551-554 (2011)
- 36) Barichello JM, Kizuki S, Tagami T, Asai T, Ishida T, Kikuchi H, Oku N, Kiwada H: Agitation during lipoplex formation improves the gene knockdown effect of siRNA. *Int. J. Pharm.* **410**, 153-160 (2011) doi: 10.1016/j.ijpharm.2011.03.001.
- 37) Honda M, Asai T, Umemoto T, Araki Y, Oku N, Tanaka M: Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. *Arch. Ophthalmol.* **129**, 317-321 (2011) doi: 10.1001/archophthalmol.2011.12.
- 38) Tokutomi K, Tagawa T, Korenaga M, Chiba M, Asai T, Watanabe N, Takeoka S, Handa M, Ikeda Y, Oku N: Decoration of fibrinogen γ -chain peptide on adenosine diphosphate-encapsulated liposomes enhances binding of the liposomes to activated platelets. *Int. J. Pharm.* **407**, 151-157 (2011) doi: 10.1016/j.ijpharm.2011.01.014.
- 39) Oku N, Yamashita M, Katayama Y, Urakami T, Hatanaka K, Shimizu K, Asai T, Tsukada H, Akai S, Kanazawa H: PET imaging of brain cancer with positron emitter-labeled liposomes. *Int. J. Pharm.* **403**, 170-177 (2011) doi: 10.1016/j.ijpharm.2010.10.001.
- 40) Shimizu K, Ida T, Tsutsui H, Asai T, Otsubo K, Oku N: Anti-obesity effect of phosphatidylinositol on diet-induced obesity in mice. *J. Agric. Food Chem.* **58**, 11218-11225 (2010) doi: 10.1021/jf102075j.
- 41) Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, Oku N: Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. *Int. J. Cancer* **127**, 2685-

2698 (2010) doi: 10.1002/jc.25276.

- 42) Dewa T, Asai T, Tsunoda Y, Kato K, Baba D, Uchida M, Sumino A, Niwata K, Umemoto T, Iida K, Oku N, Nango M: Liposomal polyamine-dialkyl phosphate conjugates as effective gene carriers: chemical structure, morphology, and gene transfer activity. *Bioconjug. Chem.* **21**, 844-852 (2010) doi: 10.1021/bc900376y.
- 43) Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N: T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. *Int. J. Pharm.* **392**, 218-223 (2010) doi: 10.1016/j.ijpharm.2010.03.022.
- 44) Hatanaka K, Asai T, Koide H, Kenjo E, Tsuzuku T, Harada N, Tsukada H, Oku N: Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography. *Bioconjug. Chem.* **21**, 756-763 (2010) doi: 10.1021/bc9005267.
- 45) Ishii T, Asai T, Urakami T, Oku N: Accumulation of macromolecules in brain parenchyma in acute phase of cerebral infarction/reperfusion. *Brain Res.* **1321**, 164-168 (2010) doi: 10.1016/j.brainres.2010.01.039.
- 46) Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, Oku N: A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy. *Cancer Lett.* **287**, 165-171 (2010) doi: 10.1016/j.canlet.2009.06.008.
- 47) Shimizu K, Osada M, Takemoto K, Yamamoto Y, Asai T, Oku N: Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane. *J. Control. Release* **141**, 208-215 (2010) doi: 10.1016/j.jconrel.2009.09.019.
- 48) Shimizu K, Kinouchi Shimizu N, Hakamata W, Unno K, Asai T, Oku N: Preventive effect of green tea catechins on experimental tumor metastasis in senescence-accelerated mice. *Biol. Pharm. Bull.* **33**, 117-121 (2010)
- 49) Urakami T, Sakai K, Asai T, Fukumoto D, Tsukada H, Oku N: Evaluation of O-[(18)F] fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. *Nucl. Med. Biol.* **36**, 295-303 (2009) doi: 10.1016/j.nucmedbio.2008.12.012.
- 50) Takahama H, Minamino T, Asanuma H, Fujita M, Asai T, Wakeno M, Sasaki H, Kikuchi H, Hashimoto K, Oku N, Asakura M, Kim J, Takashima S, Komamura K, Sugimachi M, Mochizuki N, Kitakaze M: Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. *J. Am. Coll. Cardiol.* **53**, 709-717 (2009) doi: 10.1016/j.jacc.2008.11.014.
- 51) Urakami T, Kawaguchi AT, Akai S, Hatanaka K, Koide H, Shimizu K, Asai T, Fukumoto D, Harada N, Tsukada H, Oku N: In vivo distribution of liposome-encapsulated hemoglobin determined by positron emission tomography. *Artif. Organs* **33**, 164-168 (2009) doi: 10.1111/j.1525-1594.2008.00702.x.
- 52) Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, Nishihara M, Yokoyama M, Ishida T, Kiwada H, Oku N: Particle size-dependent triggering of accelerated blood clearance phenomenon. *Int. J. Pharm.* **362**, 197-200 (2008) doi: 10.1016/j.ijpharm.2008.06.004.
- 53) Katanasaka Y, Ida T, Asai T, Maeda N, Oku N: Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. *Int. J. Pharm.* **360**, 219-224 (2008) doi: 10.1016/j.ijpharm.2008.04.046.
- 54) Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N: Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one, SU5416. *Cancer Lett.* **270**, 260-268 (2008) doi: 10.1016/j.canlet.2008.05.009.
- 55) Shimizu K, Kinouchi Shimizu N, Asai T, Tsukada H, Oku N: Enhanced experimental tumor metastasis with age in senescence-accelerated mouse. *Biol. Pharm. Bull.* **31**, 847-851 (2008)
- 56) Asai T, Miyazawa S, Maeda N, Hatanaka K, Katanasaka Y, Shimizu K, Shuto S, Oku N: Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. *Cancer Sci.* **99**, 1029-1033

(2008) doi: 10.1111/j.1349-7006.2008.00758.x.

- 57) Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H, Nango M, Oku N: Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. *Biochem. Biophys. Res. Commun.* **368**, 243-248 (2008) doi: 10.1016/j.bbrc.2008.01.074.
- 58) Imanaka H, Koide H, Shimizu K, Asai T, Kinouchi Shimizu N, Ishikado A, Makino T, Oku N: Chemoprevention of tumor metastasis by liposomal beta-sitosterol intake. *Biol. Pharm. Bull.* **31**, 400-404 (2008)
- 59) Shimizu K, Sawazaki Y, Tanaka T, Asai T, Oku N: Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug. *Biol. Pharm. Bull.* **31**, 95-98 (2008)
- 60) Yonezawa S, Asai T, Oku N: Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. *J. Control. Release* **118**, 303-309 (2007)
- 61) Ichikawa K, Urakami T, Yonezawa S, Miyauchi H, Shimizu K, Asai T, Oku N: Enhanced desensitization efficacy by liposomal conjugation of a specific antigen. *Int. J. Pharm.* **336**, 391-395 (2007)
- 62) Fuse C, Ishida Y, Hikita T, Asai T, Oku N: Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma. *J. Biol. Chem.* **282**, 8276-8283 (2007)
- 63) Katanasaka Y, Asai T, Naitou H, Ohashi N, Oku N: Proteomic characterization of angiogenic endothelial cells stimulated with cancer cell-conditioned medium. *Biol. Pharm. Bull.* **30**, 2300-2307 (2007)
- 64) Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H: In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). *Biol. Pharm. Bull.* **30**, 972-978 (2007)
- 65) Siripong P, Yahuafai J, Shimizu K, Ichikawa K, Yonezawa S, Asai T, Kanokmedakul K, Ruchirawat S, Oku N: Antitumor activity of liposomal naphthoquinone esters isolated from thai medicinal plant: *Rhinacanthus nasutus* Kurz. *Biol. Pharm. Bull.* **29**, 2279-2283 (2006)
- 66) Siripong P, Yahuafai J, Shimizu K, Ichikawa K, Yonezawa S, Asai T, Kanokmedakul K, Ruchirawat S, Oku N: Induction of apoptosis in tumor cells by three naphthoquinone esters isolated from thai medicinal plant: *Rhinacanthus nasutus* KURZ. *Biol. Pharm. Bull.* **29**, 2070-2076 (2006)
- 67) Akita N, Maruta F, Seymour LW, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J, Miyagawa S: Identification of oligopeptides binding to peritoneal tumors of gastric cancer. *Cancer Sci.* **97**, 1075-1081 (2006)
- 68) Maeda N, Miyazawa S, Shimizu K, Asai T, Yonezawa S, Kitazawa S, Namba Y, Tsukada H, Oku N: Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. *Biol. Pharm. Bull.* **29**, 1936-1940 (2006)
- 69) Shimizu K, Asai T, Fuse C, Sadzuka Y, Sonobe T, Ogino K, Taki T, Tanaka T, Oku N: Applicability of anti-neovascular therapy to drug-resistant tumor: Suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. *Int. J. Pharm.* **296**, 133-141 (2005)
- 70) Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, Namba Y, Oku N: Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. *Biochim. Biophys. Acta* **1669**, 69-74 (2005)
- 71) Goto K, Asai T, Hara S, Namatame I, Tomoda H, Ikemoto M, Oku N: Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. *Cancer Lett.* **219**, 215-222 (2005)
- 72) Yamakawa S, Asai T, Uchida T, Matsukawa M, Akizawa T, Oku N: (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. *Cancer Lett.* **210**, 47-55 (2004)
- 73) Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N: Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. *Int. J. Cancer* **108**, 301-306

(2004)

- 74) Oku N, Matsukawa M, Yamakawa S, Asai T, Yahara S, Hashimoto F, Akizawa T: Inhibitory effect of green tea polyphenols on membrane-type 1 matrix metalloproteinase, MT1-MMP. *Biol. Pharm. Bull.* **26**, 1235-1238 (2003)
- 75) Shimizu K, Takada M, Asai T, Kuromi K, Baba K, Oku N: Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno [2,1-c]quinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. *Biol. Pharm. Bull.* **25**, 1385-1387 (2002)
- 76) Asai T, Fukatsu H, Kuromi K, Ogino K, Tanaka M, Oku N, Taki T: Isolation of a novel peptide homing to tumor-derived neovasculature that suppresses tumor growth. *Biol. Pharm. Bull.* **25**, 904-906 (2002)
- 77) Shimizu K, Takada M, Asai T, Irimura K, Baba K, Oku N: Potential usage of liposomal 4 β -aminoalkyl-4'-*O*-demethyl-4-desoxypodophyllotoxin (TOP-53) for cancer chemotherapy. *Biol. Pharm. Bull.* **25**, 783-786 (2002)
- 78) Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N: Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. *FEBS Lett.* **520**, 167-170 (2002)
- 79) Oku N, Asai T, Watanabe K, Kuromi K, Nagatsuka M, Kurohane K, Kikkawa H, Ogino K, Tanaka M, Ishikawa D, Tsukada H, Momose M, Nakayama J, Taki T: Anti-neovascular therapy using novel peptides homing to angiogenic vessels. *Oncogene* **21**, 2662-2669 (2002)
- 80) Asai T, Nagatsuka M, Kuromi K, Yamakawa S, Kurohane K, Ogino K, Tanaka M, Taki T, Oku N: Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. *FEBS Lett.* **510**, 206-210 (2002)
- 81) Asai T, Shuto S, Matsuda A, Kakiuchi T, Ohba H, Tsukada H, Oku N: Targeting and anti-tumor efficacy of liposomal 5'-*O*-dipalmitoylphosphatidyl 2'-*C*-cyano-2'-deoxy-1- β -D-*arabino*-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma. *Cancer Lett.* **162**, 49-56 (2001)
- 82) Takikawa M, Kikkawa H, Asai T, Yamaguchi N, Ishikawa D, Tanaka M, Taki T, Oku N: Suppression of GD1 α ganglioside-mediated tumor metastasis by liposomalized WHW-peptide. *FEBS Lett.* **466**, 381-384 (2000)
- 83) Asai T, Kurohane K, Shuto S, Awano H, Matsuda A, Tsukada H, Namba Y, Okada S, Oku N: Antitumor activity of 5'-*O*-dipalmitoylphosphatidyl 2'-*C*-cyano-2'-deoxy-1- β -D-*arabino*-pentofuranosylcytosine is enhanced by long-circulating liposomalization. *Biol. Pharm. Bull.* **21**, 766-771 (1998)

Bibliography (Chapters and Review Articles):

- 1) Asai T and Huang L: Nanoparticle-mediated RNA interference for cancer therapy. *RNAi Therapeutics, in press*
- 2) Asai T, Oku N: Systemic delivery of small RNA using lipid nanoparticles. *Biol. Pharm. Bull.* **37**, 201-205 (2014)
- 3) Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N: Liposomes and nanotechnology in drug development: focus on ocular targets. *Int J Nanomedicine* **8**, 495-503 (2013) doi: 10.2147/IJN.S30725.
- 4) Koide H, Asai T, Shimizu K, Oku N: Drug carrier systems for anticancer agents. *Polymeric Biomaterials*, 2, chapter 6, 153-170 CRC Press (2013)
- 5) Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N: Liposomes and nanotechnology in drug development: focus on ocular targets. *Int J Nanomedicine* **8**, 495-503 (2013)
- 6) Asai T: Positron emission tomography (PET) imaging of small interfering RNA (siRNA) delivery in drug development. *Yakugaku Zasshi* **132**, 1159-1163 (2012)
- 7) Ando H, Yonenaga N, Asai T, Hatanaka K, Koide H, Tsuzuku T, Harada N, Tsukada H, Oku N: In vivo imaging of liposomal small interfering RNA (siRNA) trafficking by positron emission tomography. *Yakugaku Zasshi* **132**, 1373-1381 (2012)
- 8) Dewa, T., Asai, T., Oku, N., Nango, M.: Polyamine-lipid conjugates as effective gene carriers: chemical structure, morphology, and gene transfer activity. *Non-Viral Gene Therapy*, 243-266 In Tech (2011)

- 9) Asai, T. and Oku, N.: Angiogenic Vessel-Targeting DDS by Liposomalized Oligopeptides. *Methods in Molecular Biology*, chapter 23, **605**, 335-347 Humana Press (2010)
- 10) Koide H, Asai T, Hatanaka K, Shimizu K, Yokoyama M, Ishida T, Kiwada H, Oku N: Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers. *Yakugaku Zasshi* **129**, 1445-1451 (2009)
- 11) Shimizu, K., Akizawa, T., Asai, T., Oku, N.: Anti-angiogenic effect of green tea catechin through inhibition of membrane-type 1 matrix metalloproteinase, MT1-MMP. *Beneficial Health Effects of Green Tea*, 41-50 Research Signpost (2008)
- 12) Taki, T., Ishikawa, D., Ogino, K., Tanaka, M., Oku, N., Asai, T., Popa, I., Portoukalian, J.: A new approach for drug discovery from glycobiology and phage-displayed peptide library technology. *Biochim. Biophys. Acta.*, **1780**, 497-503 (2008)
- 13) Hatanaka K, Shimizu K, Asai T, Oku N: Antineovascular gene therapy by ago2 knockdown. *Yakugaku Zasshi* **128**, 1567-1575 (2008)
- 14) Hatanaka K, Shimizu K, Asai T, Oku N: Antineovascular gene therapy by ago2 knockdown. *Yakugaku Zasshi* **128**, 1567-1575 (2008)
- 15) Yonezawa, S., Asai, T., Oku, N.: Dorsal air sac model. *Angiogenesis assays*, 229-238 John Wiley & Sons, Ltd (2007)
- 16) Oku, N and Asai, T.: Imaging Cell Trafficking. *Molecular Imaging of the Lungs*.349-364 (2005)
- 17) Shimizu, K., Asai, T. and Oku, N.: Antineovascular therapy, a novel antiangiogenic therapy. *Expert Opin. Ther. Targets.*, **9**, 63-76 (2005)
- 18) Asai, T. and Oku, N.: Liposomalized oligopeptides in cancer therapy. *Methods Enzymol.*, **391**, 163-176 (2005)
- 19) Oku, N., Tokudome, Y., Asai, T. and Tsukada, H.: Evaluation of drug targeting strategies and liposomal trafficking. *Current Pharm. Design*, **6**, 1669-1691 (2000)